January 18, 2018 5:49pm

The sector opened down, stayed down at the mid-day and closed to the downside

 

While JUNO tripped down multiple times yet bounced back up with big volume experiencing some short-term profit taking

 

After the morning post, being right is great but, the reality of the sector needs to be defined for investors to be informed

 

Pre-open indications: 7 hits and 1 miss

 

Of interest: Caladrius Biosciences (CLBS -$0.15 ) completed enrollment in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind P2 clinical trial of 110 patients to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes (T1D).    For all their cash, they can’t get out of low gear!!

 

Out and about: The Biostage (BSTG +$0.40) chronicles … don’t be fooled by surges!


Thursday’s results have implications to Friday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

Henry’omics:

From the pre-open’s newsletter, “…the question is do you feel the sentiment? Few of the oversold will be yanked up by their heels and some will continue being dumped on their butts. The issues influencing downsizing some positions:  upcoming Q4 financial results of spending, cash positions and needed capital market access by some … along with low volume and questionable momentum. The short-term risk of sentiment is high.” …

Remember, speculation rhymes … with an eventual … portfolio castration!

As I had stated, “Overbought and oversold conditions are measured by a Moving Average Convergence Divergence or MACD indicator. The sector’s MACD indicator, sometimes correctly signals; but, indicates <to me> a short-term buy signals for some downside for the “overworked” … and scattered and small movements by most!”

Stocks are off to a strong start this year. The Dow, S&P 500 and NASDAQ are all up at least 4.8% for 2018, adding to last year's strong gains …

 

What happened to the RegMed, stem, and cell and immune-oncology therapy sector – (beyond JUNO) share pricing is seriously lagging but, CEO salaries are UP while share pricing is down grievously?

If the markets have been boasted by optimism … does that mean “our” universe is being dragged down by pessimism?

Management teams BETTER start rethinking their … APPEAL to shareholders!

Algorithms and ETFs don’t talk … but, they do buy and sell every day.

 

The advance/decline line scenario of 40 SCGT & RT covered companies:   

·         The open was negative with an A/DL of 11/23 and 6 flat ;

·         The mid-day was negative with an A/DL of 11/27 and 2 flat;

·         The close was negative with an A/DL of15/20 and 5 flat;

 

Pre-open indications:

  • Applied Genetic Technologies (AGTC) closed up +$0.05 – hit;
  • BioLife Solutions (BLFS) closed up +$0.09 – hit;
  • bluebird bio (BLUE) closed up +$6.85 – hit;
  • Fate Therapeutics (FATE) closed up +$0.22 – hit;
  • Intrexon (XON) closed down -$0.62 – hit;
  • Juno Therapeutics (JUNO) closed up +$2.12 – miss;
  • Sangamo Therapeutics (SGMO) closed up +$0.00 – hit;
  • Vericel (VCEL) closed down -$0.10 – hit;

 

 

MY working trend lines:

The greatest volume to the downside:  RENE.L, XON, NWBO, BLCM and FCSC

Upside volume was weighted to:  JUNO, CYTX, BLUE, MDXG and FATE

Biggest $ downside: ONCE (-$0.98), XON (-$0.62), BLCM (-$0.46). RGNX (-$0.33) and CLLS (-$0.30)

Largest $ upside:  BLUE (+$6.85), JUNO (+$2.12), FATE (+$0.22), MDXG (+$0.18) and AXGN (+$0.15)

Flat: AST, ONVO, BTX, SGMO and ADVM

 

 

Of interest:

 Caladrius Biosciences (CLBS -$0.15) completed enrollment in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind P2 clinical trial of 110 patients to evaluate the safety and efficacy of the Company’s CLBS03 as a treatment for recent-onset type 1 diabetes (T1D).   

CLBS’ CLBS03 is a personalized autologous cell therapy consisting of each patient's own regulatory T cells, or Tregs, which have been expanded in number and functionally enhanced by a proprietary method developed through collaboration with Jeffrey Bluestone, Ph.D. and renowned researchers at the University of California, San Francisco. 

CLBS holds exclusive rights to an international portfolio of issued and pending patents related to this product.

CLBS03 as a treatment for T1D has U.S. FDA Orphan Drug designation, European Medicine Agency Advanced Therapeutic Medicinal Product classification and FDA Fast Track designation, which represents the first T1D program to receive this distinction.

 

 

Out and about:

Biostage (BSTGD) This management team WIPED OUT 20 M of holder’s shares and investment!

Opened at $2.31 (previous closed $2.20) closed +$0.40 or +0.18% in a day’s range of $2.30 to $2.81 to close at $2.60 with low 48,731 shares traded.  This follows the projected $1.32 post the 1-to-20 reverse split – a $4 M in-flow just followed a $30 M investment loss incurring a $47 M deficit!

NO scientists, a CEO, CFO and 2 accountants don’t make a company who couldn’t pay their rent or communicate their issues to past “fleeced” shareholders …

I am NOT “eating” my negative declaration, my OPINION is still “COVER UP of male and female harassment and corporate MISDEEDS “by members of management team!

What did happen to (reasons) and the story “around” the IND NOT being filed and the cmo and president leaving the company? NEVER forget the storyline of the 2 broken financings before the reverse split!

http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11980760&type=HTML&symbol=BSTGD&companyName=Biostage&formType=3&dateFiled=2018-01-10&cik=0001563665 – VERY interesting, NO mention of BSTG’s executives!

 

 

Daily analytics:

U.S. stock benchmarks finished lower Thursday, pressured by worries over the possibility of a partial government shutdown, as investors sorted through a fresh batch of quarterly earnings results.

  • The Dow fell 97.48 points, or 0.4%, to 26,017.81.
  • The S&P 500 was off 4.53 points, or 0.2%, to 2,798.03.
  • The Nasdaq shed 2.23 points to 7,296.05.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Thursday traded at 12.22, up +2.60% …

  • Wednesday traded at 11.91, up +2.14% after Tuesday traded at 11.66, up +14.76% after Friday traded at 10.15, up +2.73%, Monday was MLK day and last Thursday traded a t9.87, up +0.51% …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Thursday was down -0.70%

·         Wednesday was up +0.96%

·         Tuesday was -1.25%

·         Monday was a market holiday;

·         Friday was up +0.40%

·         Last Thursday was up +1.69%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Thursday was down -0.13%

·         Wednesday was up +0.73%

·         Tuesday was -1.38%

·         Monday was a holiday;

·         Friday was up +0.67%

·         Last Thursday was up +0.29%

 

 

The count - decliners versus gainers:

……. look at the differences in decliners:

·         Thursday’s decliners ranged from -0.37% <STML -$0.05> to -9.68% <RENE.L -$0.15> in 20 equities;

·         Wednesday’s decliners ranged from -0.12% <BLCM -$0.01> to -6.75% <ISCO -$0.11> in 18 equities;

·         Tuesday’s decliners ranged from -0.61% <ISCO -$0.01> to -9.03% <RGNX -$2.75> in 31 equities;

·         Monday was a holiday;

·         Friday’s decliners ranged from -0.51% <ATHX -$0.01> to -7.28% <CYTX -$0.028> in 21 equities;

·         Last Thursday’s decliners ranged from -0.17% <BLUE -$0.30> to -6.47% <ADVM -$0.009> in 15 equities;

Versus

… Look at the percentage’s (%) and spreads …

·         Thursday’s gainers ranged from +0.17% <MESO +$0.01> to +18.31% <CYTX +$0.06> in 15 equities;

·         Wednesday’s gainers ranged from +0.33% <VSTM +$0.01> to +53.86% <JUNO +$23.65> in 19 equities;

·         Tuesday’s gainers ranged from +0.58% <MDXG +$0.08> to +10.13% <ADVM +$0.40> in 9 equities;

·         Monday was a holiday;

·         Friday’s gainers ranged from +0.67% <BLCM +$0.06> to +11.27% <XON +$1.49> in 19 equities;

·         Last Thursday’s gainers ranged from +0.34% <BLCM +$0.03> to +12.67% <ISCO +$0.19> in 22 equities;

 

                                  

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.